MBHS revoked:

http://www.sec.gov/litigation/admin/2014/34-73536.pdf

MBHS SEC Admin Proceeding:

http://www.sec.gov/litigation/admin/2014/34-72648.pdf

MBHS SEC Suspension:

http://www.sec.gov/litigation/suspensions/2014/34-72640.pdf

Order:

http://www.sec.gov/litigation/suspensions/2014/34-72640-o.pdf

anyone knows what's up with this stock?

I could be a possibility......
that a reverse split could happen to reduce the amount of outstanding shares. Not saying this WILL happen. Just listing a possibility imo.

03

Is this stock pretty much dead?

Will see tomorrow if this moves.

Time will tell if this will be a good runner or not. With Waka on board....who knows.

03

It will be interesting to see how this one plays out.

03

Mbeach Software Inc. Retains Wakabayashi Fund, LLC for Institutional Investor Relations and Capital Procurement Services
Date : 11/22/2011 @ 4:23PM
Source : PR Newswire
Stock : Mbeach Software (PL) (MBHS)
Quote : 0.05 0.0 (0.00%) @ 4:17PM


Mbeach Software Inc. Retains Wakabayashi Fund, LLC for Institutional Investor Relations and Capital Procurement Services
PrintAlert
Mbeach Software (PL) (USOTC:MBHS)
Intraday Stock Chart
Today : Tuesday 22 November 2011
Mbeach Software Inc. Retains Wakabayashi Fund, LLC for Institutional Investor Relations and Capital Procurement Services
PR Newswire

NEW YORK, Nov. 22, 2011




NEW YORK, Nov. 22, 2011 /PRNewswire/ -- Mbeach Software Inc. ("MBHS") (OTCPK: MBHS) announced today that the company has engaged Wakabayashi Fund, LLC ("Wakabayashi"), a Japanese and New York consulting firm, to provide investor and public relations services, capital funding services, and to present the company to institutional investors. These services will augment the funding commitment of Southridge Partners II LP to extend the company an equity line of up to $10 million per the agreement signed in August 2011.


"Wakabayashi Fund, LLC is very pleased to have been retained by Mbeach Software Inc. and share with the company's experienced management team the full scope of our services in the financial markets," said Tadaharu Wakabayashi, President of Wakabayashi Fund, LLC. "Once the company's capital needs have been met, we believe they should be well-positioned to implement their R&D to launch a market ready product for the early detection of skin cancer, apply for regulatory approvals and initiate their preliminary marketing agenda."

Mbeach, through Skin Cancer Scanning Ltd. ("SCS"), its wholly owned subsidiary, is in the advanced stages of developing a state-of-the-art medical device, SkinScan 650, which can be used by health practitioners in clinics for more accurate and early diagnostics of Skin Cancer and precursors.

Clinical trials conducted by the company so far have demonstrated a 92.4% accuracy level in diagnosing non-melanoma skin cancer (NMSC). Those results are significantly higher than the average 75% accuracy rate, achieved by dermatologists and 60% accuracy achieved by a general practitioner. Mela Sciences Inc., a developer of a similar medical product for this use, was recently reported to have obtained FDA approval for their product.

Mbeach CEO Yossi Biderman commented, "We expect that working alongside the Wakabayashi team in the implementation of the funding program and the market awareness program will greatly enhance our ability to achieve our designated goals."


About Wakabayashi Fund, LLC:Wakabayashi Fund, LLC is a private equity fund with offices in Tokyo, Japan and New York, which provides corporate capitalization and institutional investor relations consulting services. Wakabayashi Fund specializes in procuring capital for profitable and emerging small-cap and mid-cap companies, identifying institutional funding sources for its clients, and conducting various investor relations activities. Wakabayashi Fund is known for helping public companies with corporate development, corporate governance, short term and long term financing, institutionally driven sponsorship, business development, and management consulting services. To view the company's website, please visit: http://www.wakabayashifund.com/

About SCSSkin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.

Our medical device, SkinScan 650's state-of-the-art technology will enable physicians to improve their diagnostic abilities using SkinScan 650. This will replace current diagnostic procedures that have many disadvantages, such as being relatively subjective and dependent on the experience of the examiner. Errors in diagnosis can be fatal. Cancers can remain undetected, grow further and lower chances of survival. A biopsy, the intrusive removal of tissue sample, is usually needed for further diagnoses.

For more information on SCS, visit the company's new website at www.scs-med.com.

Forward Looking StatementsThis release contains forward-looking statements, including, but not limited to, statements regarding the success of an investor relations campaign, the success in obtaining funding, the future commercialization of SCS' products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

SOURCE Mbeach Software Inc.

News for MHBS

NEW YORK, Sept. 7, 2011 (GLOBE NEWSWIRE) -- mBeach Software Inc. (MBHS) (Pink Sheets:MBHS), the holding Company for Skin Cancer Scanning Ltd. (SCS) announced today that on August 31, 2011 it entered into an equity financing facility under which it may sell up to $10 million of its registered common stock to Southridge Partners II, LP over a 36-month period. MBHS is not obligated to utilize the facility and remains free to enter into other financing transactions (excluding other equity line facilities while the facility with Southridge is in effect).

MBHS will determine, at its sole discretion, the timing, dollar amount and floor price per share for any draw under this facility, subject to certain conditions. When and if MBHS elects to use the facility, the number and price of shares sold in each draw will be determined by a contractual formula, whereby MBHS will issue shares to Southridge at a pre-negotiated discount to an average closing bid price of MBHS's common stock over a preceding period of trading days.

In connection with the execution of the equity financing facility, MBHS will issue to Southridge 1,000,000 restricted shares of common stock as a commitment fee. The offer and sale of shares by MBHS under this equity facility will have to be registered pursuant to a registration statement to be filed with the Securities and Exchange Commission no later than 90 days after a certain bridge financing facility is obtained and closed.

MBHS intends to use the proceeds from any sale of securities under the facility to secure the closing of the Pomega, Inc. deal, for funding of the R&D and product development of the SkinScan 650 medical device, to secure and grow a distributor base for Pomega products, for FDA and other regulatory related matters and for working capital and other general corporate purposes.

"This equity line provides us with an important financing option," said Joseph Biderman, MBHS's Chief Executive Officer. "The facility has a competitive cost of capital and flexible structure and offers a means to fund our commitment to Pomega, Inc., strengthen our financial position and support our continuing efforts to develop our products and support the marketing campaign of Pomega, Inc. Moreover," added Mr. Biderman, "we are very pleased to have Southridge Partners II LP, a leading investment fund, as our partners in this round of financing."

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

Interesting day here for those who hold shares of mbeach. Maybe there is still life here. Maybe not. Time will be the revealer.......or not.

Regards,
03

Wow 1900% up on super low volume...

Nevermind they are MBHS again :) Holding for this future winner!!!

MBHS is now MBHSE....they better get their filing up to date...

just read article about this skinscan thing, intresting... .15 now, will watch

Did this really go to .33 the other day?

Steady climb up and a HUGE open today! open @ .755 and HOD $1.25
More to come. Either get in now while the prices are low or miss the opportunity and stay on the side lines while the rest of us make some big $$$... :) GLTA JMO

Looks like it is starting back up

jmo

what were the pps before split ?

They've got around 172 million in the float.

any one check the filings ?

this things got some legs

MBHS Daily Chart...


Thank you for your recent symbol request.

Based on your suggestion, we have added [MBHS] to our charting database:
http://stockcharts.com/h-sc/ui?s=mbhs

(((your welcome)))

Looks like we have a potential winner here.

NEWS out:

mBeach Software Inc. Targets New International Markets: Extends Global Patent Protection

TEL AVIV, Israel, Aug 18, 2010 (GlobeNewswire via COMTEX) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS) today announced the filing of additional patent applications under the framework of the Patent Cooperation Treaty (PCT). This move will facilitate the company's strategy to enter new international markets for its advanced, non-invasive system to detect and identify skin cancer.
Skin Cancer Scanning Ltd. ("SCS"), the wholly owned subsidiary, has already submitted a patent application in the United States (application number 11/464,838) with a priority date of August 2006. The patent office is currently examining this application and the company expects the patent to be approved and published by the end of 2010.

In addition to the United States, SCS has filed patent applications in many important markets around the world. These countries include Canada, Japan, Australia, China, South Korea, Singapore, New Zealand, Israel, South Africa, Brazil, Mexico, Russia and the Commonwealth of Independent States (CIS), Ukraine, and the European Union. These patent applications have now reached the national phase of registration.

"Our intellectual property is one of the company's most valuable assets," said mBeach CEO Yossi Biderman. "We are taking all necessary measures to protect this asset, including patent applications and other appropriate actions. International growth is an important part of our strategy for growth. We want to make sure we have the right patent protection in all our major potential markets as soon as possible."

About SCS

Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.

Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.

For more information on SCS, visit www.scs-med.com.